Centessa Pharmaceuticals plc
CNTADrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
4
Next Catalyst
Aug 11, 2026
5wMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
How CNTA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
cleminorexton | Phase 3 | Narcolepsy Type 1 | - | - |
ORX750 | Phase 2 | Narcolepsy Type 1 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Centessa Pharmaceuticals plc's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Centessa Pharmaceuticals plc's (CNTA) pipeline across Phase 3, Phase 2. Its lead program is cleminorexton (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Centessa Pharmaceuticals plc's next FDA catalyst?→
Centessa Pharmaceuticals plc's (CNTA) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CNTA biotech catalysts?→
Add CNTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Centessa Pharmaceuticals plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.